1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
MiMedx Group, Inc.

MiMedx Group, Inc.

MDXG
MiMedx Group, Inc.US flagNASDAQ Capital Market
4.71
USD
-0.06
- -
686.53MMarket Cap
MiMedx Group, Inc.
MDXG
(NASDAQ Capital Market)

Recent

price

4.71

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.01
0.11
0.33
0.61
1.12
1.77
2.09
3.03
3.35
2.8
2.29
2.19
2.37
2.76
2.37
2.83
2.4
Revenue per Share
-0.19
-0.14
-0.09
-0.04
0.06
0.28
- -
0.61
-0.28
-0.24
-0.47
-0.16
-0.33
0.44
0.29
0.33
0.04
Basic EPS, GAAP
-0.14
-0.1
-0.05
-0.03
0.13
0.11
0.16
0.54
0.24
-0.39
-0.32
-0.05
-0.18
0.21
0.44
0.49
0.28
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.09
0.16
0.23
0.7
0.83
1.01
1.21
0.68
0.46
0.31
- -
- -
-0.16
0.98
1.31
1.73
1.48
Book Value per Share
0.02
-0.1
0.05
0.56
0.69
0.87
0.81
0.4
0.18
0.06
-0.24
-0.23
-0.38
0.81
1.1
1.51
1.27
Tangible Book Value per Share
59
72
82
96
106
106
106
106
107
107
108
110
113
116
147
148
148
Basic Weighted Avg Shares
1
8
27
59
118
187
222
321
359
299
248
242
268
321
349
419
355
Sales/Revenue/Turnover
-1,335.15
-125.7
-7.36
-3.84
6.01
13.01
0.4
14.39
-1.09
-6.92
-17.87
-2.89
-5.5
11.55
17
15.26
2.46
Operating Margin (%)
1
2
2
2
2
3
5
6
7
8
7
5
4
3
6
15
12
Depreciation Expense
-11
-10
-8
-4
6
29
- -
65
-30
-26
-49
-12
-30
58
42
49
6
Net Income, GAAP
- -
- -
- -
- -
11.8
- -
28.44
- -
- -
- -
- -
- -
- -
- -
26.7
26.69
45.9
Effective Tax Rate (%)
-1,447.6
-131.36
-28.33
-6.95
5.26
15.72
0.18
20.16
-8.35
-8.55
-19.85
-5.08
-11.27
18.11
12.16
11.6
1.76
Profit Margin (%)
- -
2
13
56
67
70
76
3
3
56
101
106
91
118
146
213
167
Working Capital
- -
3
4
- -
- -
- -
- -
- -
- -
62
48
48
49
48
18
16
16
LT Debt
6
12
20
74
89
108
133
74
50
34
- -
- -
-18
143
193
257
216
Total Equity
- -
- -
- -
- -
7.69
- -
0.51
- -
- -
- -
- -
- -
- -
- -
21.88
19.74
2.11
Return on Invested Capital (%)
- -
- -
- -
- -
7.69
- -
0.32
- -
- -
- -
- -
- -
- -
- -
21.38
19.97
2.76
Return on Capital (%)
-187.63
-113.28
-48.04
-8.79
7.64
29.85
0.32
62.6
-48.57
-60.87
- -
- -
- -
- -
25.26
21.61
2.88
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
2
2
2
LT Borrowings
16
16
16
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
148
149
146
Market Capitalization
1,003
588
561

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
277
240
205
Cash, Cash Equivalents & STI
166
160
136
Accounts Receivable, Net
76
46
41
Inventories
25
26
21
Total Current Liabilities
64
45
38
Payables & Accruals
26
22
19
ST Debt
2
2
2
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-2,320.17%
-4,603.3%
32.85%
Free Cash Flow
10.65%
31.89%
13.11%
Net Income, GAAP
1,609.46%
-47%
14.52%
Sales/Revenue/Turnover
9.8%
11.34%
19.99%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
85
87
84
93
349
2025
88
99
114
118
419
2026
59
64
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.06
0.12
0.06
0.05
0.29
2025
0.05
0.07
0.11
0.1
0.33
2026
-0.07
-0.1
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Sona Nanotech Inc. (SONA.CN)
Tengion, Inc. (TNGNQ)
Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (2566.HK)
Theralink Technologies, Inc. (THER)
Janux Therapeutics, Inc. (JANX)
Entero Therapeutics, Inc. (ENTO)
Business
MiMedx Group, Inc. is a biopharmaceutical enterprise dedicated to developing and commercializing regenerative biomaterial products and bioimplants derived from human placental tissues. The company employs its patented and proprietary PURION process to prepare these allografts, ensuring the retention of the tissue’s inherent biological properties, including crucial regulatory proteins. This distinctive processing method incorporates aseptic techniques alongside terminal sterilization to deliver robust solutions. Its portfolio encompasses a variety of advanced tissue-based products. EpiFix, a flagship offering, is a dehydrated human amnion/chorion membrane allograft designed as a protective barrier for persistent wounds such as diabetic foot ulcers, venous leg ulcers, and pressure ulcers. AmnioFix, also a dehydrated human amnion/chorion membrane allograft, serves in surgical recovery, including applications in orthopedics, spine, and sports medicine. A micronized injectable form of AmnioFix, known as mdHACM, is currently under clinical investigation for conditions like knee osteoarthritis, having received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA. EpiCord, a dehydrated human umbilical cord allograft, leverages hyaluronic acid and collagen to foster a healing environment in advanced wound care and surgical settings. Recent additions include EPIEFFECT, a lyophilized placental-based allograft introduced in September 2023 for acute and chronic wounds, and EPIXPRESS, a next-generation lyophilized placental allograft launched in October 2025 that features fenestrations for enhanced fluid movement. The company's products primarily address needs in advanced wound care, burn treatment, and surgical recovery. Additionally, MiMedx supplies allografts for ophthalmic and dental applications through various partnerships. The distribution model relies on a direct sales force, independent sales agents, and distributors, predominantly within the United States, including federal healthcare agencies. Recent strategic initiatives include a July 2025 collaboration with Vaporox, Inc. to co-promote wound care offerings, coupled with a strategic investment. Headquartered in Marietta, Georgia, MiMedx Group, Inc. reported record quarterly revenue of $114 million in Q3 2025 and full-year 2024 revenue of $349 million.

Company News

Company News APIChatGPT

  • defenseworld.net

    Compugen (NASDAQ:CGEN) versus MiMedx Group (NASDAQ:MDXG) Head-To-Head Comparison

  • defenseworld.net

    Protagonist Therapeutics (NASDAQ:PTGX) & MiMedx Group (NASDAQ:MDXG) Head-To-Head Review

  • globenewswire.com

    MIMEDX Announces Favorable Federal Court Ruling in AXIOFILL® Regulatory Classification Matter

  • businesswire.com

    Sanara MedTech Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sanara MedTech Inc. - SMTI

  • globenewswire.com

    MIMEDX to Participate in Upcoming Investor Conferences

  • defenseworld.net

    Deutsche Bank AG Takes $520,000 Position in MiMedx Group, Inc $MDXG

  • businesswire.com

    Sanara MedTech Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sanara MedTech Inc. - SMTI

  • seekingalpha.com

    MiMedx Group, Inc. (MDXG) Q2 2026 Earnings Call Transcript

  • marketbeat.com

    MiMedx Group Q2 Earnings Call Highlights

  • globenewswire.com

    MIMEDX Announces Second Quarter 2026 Operating & Financial Results

  • globenewswire.com

    MIMEDX to Acquire Sanara MedTech

  • globenewswire.com

    MIMEDX to Host Second Quarter 2026 Operating and Financial Results Conference Call on July 29

  • prnewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, Inc. - MDXG

  • globenewswire.com

    MIMEDX to Participate in Craig-Hallum 23rd Annual Institutional Investor Conference

  • globenewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, Inc. - MDXG

  • gurufocus.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, Inc. - MDXG

  • prnewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, Inc. - MDXG

  • globenewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, Inc. - MDXG

  • zacks.com

    Is the Options Market Predicting a Spike in MiMedx Group Stock?

  • seekingalpha.com

    MiMedx: The Hard Math Behind My Downgrade To Hold